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Abstract
Background: The BD MAX™ Enteric Bacterial Panel (BDM-EBP) is designed and FDA-cleared to detect Salmonella,
Shigella, Campylobacter, and Shiga toxin genes stx1/2 from stool samples. However, rectal swabs, which are not
FDA-cleared for clinical testing with the BDM-EBP, are common specimens received from pediatric patients for
enteric pathogen testing. The purpose of this study was to evaluate the ability of the BDM-EBP to detect stool
pathogens from rectal swabs.
Methods: Routine cultures, Shiga toxin testing, and molecular testing with BDM-EBP were performed on 272
sequential rectal swabs collected from August 2015 to December 2015. Discrepant test results were resolved using
Verigene® Enteric Pathogens Nucleic Acid Test (EP). 36 challenge samples (13 Salmonella spp., 3 Shigella spp., 10
Campylobacter spp., and 10 Shiga toxin positive Escherichia coli) were tested using reference strains (American Type
Culture Collection) and previous patient isolates diluted to103-104 cfu/ml in saline then added to Sample Buffer
Tube (SBT) with negative stool matrix delivered via a swab. Limit of detection testing was performed by serial 10
fold dilutions in saline then added to SBT with negative stool matrix provided via a swab.
Results: A total of 272 rectal swab specimens were evaluated and 89 were positive by culture and/or MAX EBP.
All discrepant results were BDM-EBP positive and culture negative. 21 of 31 (68%) of the apparent false positive
BDM-EBP discrepant results resolved as positive with Nanosphere’s Verigene® EP. After resolution of the
discordant results, the Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) are as follows
for each target: Salmonella (n = 4) 100%, PPA and 100%, NPA; Shigella (n = 79) 100%, PPA and 95.3%, NPA;
Campylobacter (n = 4) 100%, PPA and 99.6%, NPA; and Shiga toxin producing organisms (n = 2) 100%, PPA and
100%, NPA. 8.8% of the patient samples did not initially yield a result on the BDM-System. Upon repeat, half of
the problematic samples resolved, and 4.4% of the total specimen tested did not yield a result. All organisms in
the challenge samples were detected. Limits of detection for BDM-EBP testing of rectal swabs were as follows (in
cfu/ml in SBT): Salmonella-1.44 × 102; Shigella-5.10 × 100; Campylobacter-1.51 × 101; and Shiga Toxin-1.13 ×103.
Conclusion: Rectal swabs are acceptable samples for detecting Salmonella, Shigella, Campylobacter, and Shiga
toxin using BDM-EBP.
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Background
According to the World Health Organization reports,
there are nearly 1.7 billion cases of diarrheal disease
worldwide every year [1, 2]. In addition, this disease is
the second leading cause of death worldwide for chil-
dren under 5 years of age, killing nearly 760,000 [1, 2].
Repeated bouts of diarrhea and persistent diarrheal dis-
ease disrupt intestinal function and absorption, making
diarrheal disease a leading cause of malnutrition in this
same age group [1, 2]. Importantly, diarrheal disease is
both treatable when correctly diagnosed and prevent-
able via proper infection control measures.
In the United States, Salmonella, Campylobacter, Shi-
gella, and Shiga toxin-producing Escherichia coli are the
most common bacterial pathogens, and they are usually
associated with foodborne illnesses. Identifying the cause
of diarrhea is important for the treatment of patients
and for public health intervention through outbreak
management.
The BD MAX™ Enteric Bacterial Panel (BDM-EBP)
from BD Diagnostic Systems (Quebec, Canada) identifies
Salmonella, Campylobacter, Shigella, and Shiga toxin-
producing E. coli via multiplex PCR. The BDM-EBP is
FDA-cleared to detect these four pathogens from fresh
stool cultures and stool preserved in Cary-Blair. In a
large, multi-centered study comparing BDM-EBP with
stool culture for fresh and preserved stool specimen, the
Positive Percent Agreement (PPA) and Negative Percent
Agreement (NPA) were as follows: Salmonella−97.3%
PPA, 99.8% NPA; Shigella−99.2% PPA, 100% NPA; Cam-
pylobacter−97.5% PPA, 99.0% NPA; and Shiga toxin pro-
ducing organisms−100% PPA, 99.7% NPA [3]. However,
rectal swabs, which are not FDA-cleared for clinical test-
ing with the BDM-EBP, are common specimens received
for stool pathogens. Rectal swabs are widely accepted to
be an appropriate sample type for infants and patients
that cannot pass a stool specimen [4, 5]. The application
of nucleic acid amplification to this sample type would
have a significant impact on diagnosis and treatment as
well as understanding the epidemiology of this disease,
particularly in very young children. The purpose of this
study was to evaluate the ability of the BDM-EBP to
detect stool pathogens from rectal swabs.
Methods
Clinical samples
From August 2015 to December 2015, 272 sequential
rectal swab samples (dual swab; BBL CultureSwab (BD)
in liquid Stuart) were collected from patients at Cincin-
nati Children’s Hospital Medical Center (CCHMC) for
conventional bacterial culture and Shiga Toxin testing,
as standard of care. One swab was plated onto BBL
Trypticase Soy Agar with 5% Sheep Blood, MacConkey
II Agar, Hektoen Enteric Agar, MacConkey II Agar with
Sorbitol, and Campy CVA Agar (BD Diagnostic Sys-
tems, Sparks, MD, USA) and incubated following
standard protocols. Colonies consistent with enteric
bacterial pathogens were identified using Vitek 2 GN
identification cards (bioMerieux, Durham, NC, USA),
conventional biochemical reactions, MALDI-ToF, and
serogrouping. After inoculating the agar plates for
standard of care, the “remnant” swab was placed into a
SBT, vortexed, and removed. Testing of the SBT was
carried out with the BDM-EBP according to the manu-
facturer’s package insert: the SBT was mixed and
placed on the instrument with extraction reagents and
master mix, where the nucleic acid extraction, amplifi-
cation, and detection occurred. Shiga-toxin EIA testing
was performed on the second swab in the rectal swab
collection device using MacConkey Broth (Remel,
Lenexa, KS) and the Immunocard STAT! EHEC test
method (Meridian, Bioscience, Cincinnati, OH) accord-
ing to the manufacturer’s instructions. All SBTs were
frozen at−80 °C for future testing, if needed. Prior to
evaluating the performance of BDM-EBP with rectal
swab specimens, a preliminary study was done to as-
sess if inoculating swabs onto agar plates before inocu-
lating the BDM-SBTs impacted the amount of
organism present or inhibited detection by PCR. The
findings showed that BDM-EBP detection of various
dilutions of Salmonella enterica subsp. enterica serovar
Typhimurium (ATCC 14028) was similar for swabs
streaked first on HE agar plates (BD Diagnostic Sys-
tems, Sparks, MD, USA) and swabs placed directly in
BDM-SBT directly, confirming that the bacterial load
was not impacted for PCR testing (data not shown).
Discordant analysis
Discordant analysis was performed on the SBT employ-
ing the Verigene® EP (Enteric Pathogen) kit on the Ver-
igene System (Nanosphere, Northbrook, IL) using a
modification of manufacturer’s protocol. The SBT was
also sub-cultured to appropriate agar plates to enhance
the isolation of the pathogen. The previously frozen
SBT was thawed and mixed thoroughly with a vortex.
300 μl of the SBT was placed into a micro-centrifuge
tube and several drops were plated onto appropriate
media and incubated accordingly. Stool matrix
prescreened by BDM-EBP and Verigene® EP and deter-
mined to be negative was added to the micro-
centrifuge tube via a swab. The contents of the tube
were mixed thoroughly and spun at 2000 rpm for 30 s.
200 μl of the SBT/stool matrix mix was added to the
extraction tray. The extraction tray was capped and
loaded into the Nanosphere processor with the tips,
reagent tray, and Verigene® EP test cartridge where
testing was performed.
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Statistical analysis
Positive percent agreement (PPA) and negative percent
agreement (NPA) between BDM-EBP and culture/EIA
were calculated for clinical samples for each target, as
appropriate.
Challenge samples
Thirty-six additional contrived samples (3 Shigella spp., 13
Salmonella spp., 10 Campylobacter spp., and 10 E. coli iso-
lates known to produce Shiga toxin) were also tested. Refer-
ence strains (American Type Culture Collection) and
previous patient bacterial isolates were diluted to a final
density of 103-104 cfu/ml in saline. 10 μl of the dilution was
added to a SBT. Negative stool matrix was added to the
SBT via swabs and tested with the BDM-EBP kit on the
BDM instrument.
Limit of detection
To determine the limit of detection for each target, a 0.5
McFarland suspension of each organism was made: Sal-
monella enterica subsp. enterica serovar Typhimurium
ATCC 14028, Shigella sonnei ATCC 9290, Campylobacter
jejuni ATCC 33291, and E. coli ATCC 43890. Ten-fold
serial dilutions of each organism were performed using
saline. In triplicate, 10 μl of each dilution was plated onto
appropriate agar plates and incubated at 35 °C ambient air
for 24 h (42 °C, microaerophilic conditions for 72 h for C.
jejuni). 100 μl of each dilution was inoculated into Sample
Buffer Tubes (SBTs) in triplicate. To replicate the rectal
swab sample type, stool matrix prescreened with BDM-EBP
and Verigene® EP and determined negative was added to
each SBT by dipping the swab into the matrix then swirling
in the SBT. Each SBT was tested with the BDM-EBP kit on
the BDM instrument.
Results
A total of 272 patient rectal swabs were received into
the laboratory at the time of an outbreak of Shigella
species. Of the 89 positive samples detected, 31 yielded
discrepant results between culture and BDM-EBP: 28
Shigella sp., 1 Salmonella sp., 1 Campylobacter sp., and
1 Shiga Toxin producing organism (Table 1). All were
culture negative and BDM-EBP positive.
The residual SBTs for 21 of the 31 culture negative/
BDM-EBP positive samples were also positive by Veri-
gene® EP, using the modified protocol (Table 2). No
additional positive samples were detected sub-culturing
SBT to agar media. After resolution testing, the Positive
Percent Agreement (PPA) and Negative Percent Agree-
ment (NPA) were as follows for each target: Salmonella
(n = 4) 100%, PPA and 100% NPA; Shigella (n = 79)
100%, PPA and 95.3%, NPA; Campylobacter (n = 4)
100%, PPA and 99.6%, NPA; and Shiga toxin producing
organisms (n = 2) 100%, PPA and 100%, NPA. The assay
limit of detection for simulated rectal swab specimens
ranged from 5–1130 cfu/ml in SBT (Table 3), and the 4
targets were correctly detected in all of the contrived chal-
lenge specimens.
Discussion
In this study, 31 rectal swabs were positive by BDM-EBP
but were negative by culture, suggesting that BDM-EBP
is more sensitive than culture for detecting bacterial
stool pathogens from rectal swabs. While it is possible
that these BDM-EBP results are false positives, this is
unlikely as 68% of these discrepant samples were also
found to be positive by the Verigene® EP. The ability of
the BDM-EBP to detect additional positives is likely the
result of improved sensitivity compared to culture of
rectal swabs and this is finding is consistent with the
assay limit of detection for the 4 targets, using simulated
rectal swab specimens.
In a large, multi-centered study comparing BDM-EBP
with stool culture for fresh and preserved stool specimen,
the PPA and NPA were as follows: Salmonella−97.3%
PPA, 99.8% NPA; Shigella−99.2% PPA, 100% NPA; Cam-
pylobacter−97.5% PPA, 99.0% NPA; and Shiga toxin pro-
ducing organisms−100% PPA, 99.7% NPA [3]. The PPA
and NPA between culture/Shiga toxin EIA and BDM-EBP
for rectal swab specimens following resolution of discord-
ant results are similar in the present study.
The swab transport is a critical component to the
study. Cloud, et al. reports that the material at the tip of
the swab can inhibit the PCR reaction [6]. Rayon or
polyester is acceptable material for the PCR reaction [6].
The swab utilized within the CCHMC healthcare system
is the BBL CultureSwab Dacron in liquid Stuart medium.






BDM- Positive BDM- Negative
Shigella 51 28 193
Salmonella 3 1 268
Campylobacter 3 1 268
Shiga Toxina 1 1 270
a104 Single swabs received. Shiga Toxin EIA not performed




(% of discrepant results)
Target Positive Negative
Shigella (n=28) 19 (68%) 9 (32%)
Salmonella (n=1) 1 (100%) 0 (0%)
Campylobacter (n=1) 0 (0%) 1 (100%)
Shiga Toxin (n=1) 1 (100%) 0 (0%)
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Newer flocked swabs are designed to have more sampling
area to collect more sample, as well as release more speci-
men into the medium. ESwab™, which utilizes the flocked
swab in 1 ml Amies medium, allows for liquid testing and,
thus, could be easily used on the BDM-System. However,
ESwab™ is not FDA-cleared for testing with the BDM-
System and must be validated by the user.
One of the limitations of this study was the low num-
ber of Salmonella, Campylobacter and Shiga toxin posi-
tive rectal swabs obtained. Although all the contrived
specimens tested were correctly identified, true patient
specimens that are positive are ideal. As rectal swabs
are not an approved sample type for any multiplex
gastrointestinal panel, discordant analysis relied on
using Nanosphere’s Verigene® EP to test the SBT in an
off-label manner. Preferably, an alternate PCR with
bidirectional amplicon sequencing would be used to
resolve discrepant results, but this testing was beyond
the scope of this study [3].
The initial rate for patient specimens where no result
was obtained was 8.8%. Upon a single repeat, 50% of
the problematic specimens resolved, and the final per-
centage of total specimens tested with no result was
4.4%. Review of a large multi-center study indicated ini-
tial unresolved rates of 5.0% with some sites reporting
initial unresolved rates of 7.7% and 10%. Upon repeat
of the initial SBT, the unresolved rate dropped to 1.3%
with the same sites reporting repeat unresolved rates of
1.6% and 4.5% respectively. This study also indicated
unpreserved specimen had higher unresolved rates than
preserved specimen. Dilution of the stool matrix in
Carey-Blair thus reducing inhibitory substances was
given as a plausible explanation for the differing unre-
solved rates [3].
Conclusion
Although stool is the optimal specimen for identifying
enteric bacterial pathogens, PCR from swabs is more
sensitive than culture from swabs, and rectal swabs can
be used for testing with BDM-EBP for detection of Sal-
monella spp., Shigella spp., Campylobacter spp., and
Shiga toxin 1 and 2 genes. Additionally, BDM –EBP
PCR results are available 34–47 h sooner that with
conventional cultures from rectal swabs [7]. Early
detection will aid in epidemiology and managing the
spread of these bacterial pathogens. The application of
nucleic acid testing with the BDM-EBP to rectal swabs
has the potential to increase pathogen identification of
diarrheal disease. This is particularly true among the
very young, the population most at risk for mortality
from untreated diarrheal disease.
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